Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of bevacizumab plus erlotinib versus gemcitabine/cisplatin plus bevacizumab in inoperable non-squamous advanced NSCLC
2006-004865-32Phase 2Completed
- Sponsor
- Aktion Bronchialkarzinom
- Start
- Feb 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Erlotinib + bevacizumab with Gemcitabine + cisplatin + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Feb 2007; status: completed.
02
Drugs
bevacizumaberlotinibgemcitabinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-004865-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004865-32.